This clinical trial is focused on studying a type of cancer known as Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas. This condition involves a group of cancers that have returned or are resistant to treatment and are associated with the Epstein-Barr virus. The trial is testing a combination of two medications: Nanatinostat and Valganciclovir. Nanatinostat, also known by its code name VRx-3996, is a chemical compound taken as a coated tablet. Valganciclovir is another chemical compound used in this study, also taken orally.

The purpose of the study is to evaluate how well the combination of Nanatinostat and Valganciclovir works in treating these lymphomas. Participants in the study will receive these medications over a period of time, and their response to the treatment will be monitored. The study aims to see if the combination can reduce the size of the tumors or slow their growth. The trial will also look at how long the response lasts, the time until the next treatment is needed, and overall survival rates.

Throughout the study, participants will be closely observed to assess the effectiveness of the treatment and any side effects. The trial is designed to gather information on how the body processes the medications, including how long it takes for the drugs to reach their highest concentration in the blood and how long they stay in the system. This information will help determine the potential benefits of the treatment for patients with EBV+ relapsed/refractory lymphomas.